# Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis

> **NCT03720340** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Recombinant Human Interleukin-11
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT03720340
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2022-08-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720340, "Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03720340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*